Waters Corporation WAT
- Market cap
- $42.3B
- P/E
- 108×
Follow WAT
Waters Corporation (WAT) Free cash flow
Waters Corporation's free cash flow for fiscal 2025 was $507.6M, down 18.1% from $619.6M in fiscal 2024. Over the twelve months to 30 June 2026 it was $366.6M. Over the past ten years it has ranged from −$840.2M (fiscal 2023) to $619.6M (fiscal 2024); the current reading is higher than 45% of that period. Waters Corporation ranks 15th of 52 Diagnostics & Research companies by free cash flow.
Free cash flow, annual
Annual
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $507.6M | (18.08%) |
| FY2024 | $619.6M | — |
| FY2023 | −$840.2M | — |
| FY2022 | $428.2M | (26.05%) |
| FY2021 | $579.0M | 7.71% |
| FY2020 | $537.6M | 12.17% |
| FY2019 | $479.3M | (5.72%) |
| FY2018 | $508.4M | (16.27%) |
| FY2017 | $607.2M | 10.00% |
| FY2016 | $552.0M | 16.11% |
Quarterly
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $153.0M | — |
| Mar 2026 | −$42.0M | — |
| Dec 2025 | $93.4M | (42.45%) |
| Sep 2025 | $162.2M | 801.28% |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| IQV IQVIA Holdings Inc. compare | $2.3B |
| DGX Quest Diagnostics Incorporated compare | $1.3B |
| A Agilent Technologies, Inc. compare | $1.3B |
| IDXX IDEXX Laboratories, Inc. compare | $1.2B |
| ILMN Illumina, Inc. compare | $931.0M |
| MTD Mettler-Toledo International, Inc. compare | $864.0M |
| WAT Waters Corporation | $366.6M |
| NTRA Natera, Inc. compare | $84.2M |
| GH Guardant Health, Inc. compare | −$240.7M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on WAT
- Revenue
- Net income
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement